Objective: Currently, there are no accepted nonsurgical therapies that improve the delivery of blood-derived nutrients to patients with critical limb ischemia. Here, we describe the ongoing phase 1/2 Clinical and Histologic Analysis of Mesenchymal Stromal Cells in AmPutations (CHAMP) trial, which will provide crucial evidence of the safety profile of mesenchymal stromal cells (MSCs) and explore their therapeutic mechanisms in the setting of critical limb ischemia requiring below-knee amputation (BKA).
Critical limb ischemia (CLI) refers to a pathologic state in which blood flow to the leg is insufficient to deliver the resting metabolic needs of skeletal muscle. Unfortunately, those who are not candidates for surgical revascularization, the "gold standard" therapy, are at a higher risk of amputation secondary to refractory pain or persistent infection. 1 Cell-based therapies represent a potential treatment for patients without a suitable revascularization option, but the mechanism of action by which this occurs has yet to be clearly defined. Intramuscular (IM) injection of concentrated bone marrow aspirate (cBMA), containing CD34 þ proangiogenic hematopoietic progenitor cells (PHCs) and mesenchymal stromal cells (MSCs), has shown promise in small case series and large randomized controlled trials alike. [2] [3] [4] [5] [6] However, the source of cBMA must be autogenous, given a robust host rejection response, and therefore it is limited by the comorbidities of the treated patient. MSCs, as an isolated treatment product, potentially represent a more efficacious therapy as they do not constitutively express major histocompatibility complex (MHC) class II molecules and largely escape host immune recognition, allowing the use of healthy allogeneic donors for diseased hosts. 7 The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.
METHODS

Synopsis. Clinical and Histologic Analysis of Mesenchymal Stromal Cells in AmPutations (CHAMP) is a
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https://doi.org/10.1016/j.jvs.2017.09.057 single-center, phase 1/2, open-label clinical trial that will enroll 32 total CLI patients requiring semielective belowknee amputation (BKA) within 30 days for rest pain or dry gangrene. The Indiana University Institutional Review Board (No. 1510579216A015) reviewed and approved the trial protocol, which was designed in concordance with the latest iteration of the Declaration of Helsinki. 8 After informed consent is obtained, participants receive IM injections of autogenous cBMA or allogeneic MSCs along the distal thigh, the gastrocnemius, and the proximal aspect of the tibialis anterior before randomization to BKA and tissue harvest at four time points within 21 days.
cBMA and MSC preparation. The protocol for harvest, concentration, and injection of cBMA has been described by our group in detail elsewhere. 3 In short, a large-bore needle is inserted into the superior iliac crests under local anesthesia, and approximately 330 mL of bone marrow is aspirated. The MarrowStim PAD Kit (Zimmer Biomet, Warsaw, Ind) is used to create 33 mL of cBMA from this dilute suspension through centrifugation. Small aliquots (w1 mL) of the treatment product are injected into the muscle beds of the BKA myocutaneous flap and proximal tibialis anterior at set points. Subjects enrolled into the MSC cohort are typed for human leukocyte antigen A2 (HLA-A2) before selection of appropriately mismatched MSCs to allow ease of identification between host and donor at the time of tissue harvest through fluorescent in situ hybridization. HLA-A2 À subjects will receive HLA-A2 þ donor cells, and Inclusion and exclusion, randomization, and treatment. All patients with CLI between the ages of 40 and 80 years, without clinical evidence of infection, requiring BKA within 30 days are eligible for inclusion into the cBMA or MSC cohorts (Table I) . Screening protocols, treatment timing, and follow-up schedule are detailed in Table II . Patency of lower extremity arteries is not routinely performed as part of the CHAMP screening protocol.
Computer-assisted, nonstratified randomization is performed to assign patients to BKA and tissue harvest at days 3, 7, 14, or 21 after injection (Fig 1) . Cells are administered into 25 different sites within the gastrocnemius and distal thigh (Fig 2) muscle beds that compose the BKA myocutaneous stump. An additional injection point at a fixed point from the tibial tuberosity is performed in the most proximal aspect of the tibialis anterior for downstream mechanistic analysis. Tissue from the untouched soleus of the deep posterior compartment serves as an internal control.
Tissue harvest. Before BKA on the assigned day, the patient is subjected to a clinical limb perfusion evaluation with ankle-brachial index, toe-brachial index, transcutaneous oximetry, and indocyanine angiography for comparison to baseline studies. Intraoperatively, at least four muscle samples from the tibialis anterior in 2-cm increments distal to the cellular injection point are collected for downstream applications. Amputation proceeds in study patients in the standard fashion for our institution, consisting of the anterior rotation of a posterior compartment myocutaneous flap.
End points and follow-up. Through a review of adverse events by clinic visits during 6 months after the procedure, we plan to test the hypothesis that autogenous cBMA and allogeneic MSCs do not result in significant cardiovascular, respiratory, or infectious complications (Table II) . Peripheral blood is also collected from the patients at days 3, 14, 45, 90, 135, and 180 and compared with baseline test results to determine changes in peripheral cytokine signaling, microRNA expression, and proangiogenic and inflammatory mononuclear phenotypes. Tissue collected at time of amputation will be subject to multiplex arrays, immunohistochemistry, fluorescence-activated cell sorting, and fluorescent in situ hybridization. In this way, we can characterize histologic appearance of muscle, local proangiogenic cytokine expression, inflammatory cell infiltrates, donor MSC retention, and the clinically important measure of capillary density at various time points after treatment. The plan for statistical analysis of data points isolated is detailed in the Supplementary Methods (online only).
Additional clinical investigations will be made into the clinical efficacy of MSCs and cBMA in promoting freedom from gangrene, above-knee amputation conversion, and death after BKA. Treatment groups will be compared with patients who qualified for CHAMP but declined participation.
Current status. Recruitment for CHAMP is ongoing, and the first 10 patients have been treated per protocol. Anticipated conclusion of recruitment, treatment, and follow-up will be within 24 months.
DISCUSSION
When amputation is required, below-knee creation of a myocutaneous stump is preferred as knee preservation decreases energy expenditure for prosthesis-assisted ambulation. 10, 11 However, contemporary proximal conversion rates secondary to stump ischemia are reported at 20%, creating massive morbidity for the patient and increasing the overall health care burden. [11] [12] [13] Therefore, the effort to reduce BKA failure represents an important area of research for all patients with CLI. CHAMP will be decisive in characterizing the biologic activity of allogeneic MSCs in human tissue. The idea for this study matured secondary to completion of our previous open-label phase 1 trial investigating the utility of IM injections of cBMA containing MSCs into 30 limbs with nonrevascularizable CLI. We found that these patients exhibited 1-year and 5-year amputation free survival rates of 86% and 74%, respectively, which is comparable to the CLI population that receives surgical revascularization. 6 In addition, we noted improvements Regimented 6-month follow-up Untouched soleus muscle will serve as an internal tissue control and is harvested concurrently.
amputation in nonrevascularizable CLI patients with the caveat that they are not diabetic and do not have Rutherford class 5 disease. The number needed to treat to prevent one amputation was merely six patients. 3 Although these studies reported promising results, several glaring limitations have prevented the advancement and adoption of cell-based therapy as a widespread treatment modality. First, isolation of autologous cells requires a harvest procedure under anesthesia, placing CLI patients, often of advanced age and severe cardiovascular comorbidities, at risk for additional complications. Second, autologous stem cells from patients with cardiovascular disease have shown limited neovascularization ability in experimental stroke and heart disease models compared with healthy controls. [14] [15] [16] MSCs, on the other hand, can be sourced from healthy allogeneic donors and injected into diseased limbs because of reduced constitutive MHC class II molecule expression, bypassing the limitations of cell-based therapies. 7 This readily available, unique subset of cells has demonstrated the ability to induce angiogenesis, to decrease muscle fiber apoptosis, and to stimulate re-epithelialization of wound beds. [17] [18] [19] Our preliminary unpublished in vitro experiments indicated that MSCs secrete increased quantities of the proangiogenic cytokines vascular endothelial growth factor, hepatocyte growth factor, and angiopoietin 1 in response to hypoxic conditions. However, the current overall understanding of the bioactivity of this subset of stem cells arises entirely from in vitro or animal studies, which are limited by poor generalizability and genomic discordance in pathologic conditions. 17, 20, 21 The lack of clarity regarding MSC bioactivity in ischemic human tissue continues to be a problem despite multiple clinical trials. [22] [23] [24] Initially, MSCs were thought to engraft, differentiate, and replace damaged tissue. However, subsequent work has established low levels of engraftment (<0.1%) of donor cells. 20 Current opinion reflects a mechanism of crosstalk between MSCs and injured cells to limit tissue destruction and to enhance repair. Specifically, this phenomenon may occur secondary to secretion of bioactive proteins that act in a paracrine or autocrine fashion, upregulation of genes that inhibit excessive inflammatory and immune reactions, and transfer of vesicular components that contain mitochondria and microRNA (exosomes). 21 The MSC dosage selected in CHAMP was based on mouse models (by body surface area) and previous clinical trials, notably Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON), in which MSCs were directly injected into the myocardium. 22 Therefore, it is entirely possible that we may not observe efficacy secondary to inadequate dosing. In addition, the primary goal of this phase 1/2 trial is to assess safety, and therefore it is not powered for clinical efficacy end points.
To describe the bioactivity of allogeneic MSCs in ischemic muscle, we plan to define donor MSC retention over time, host immune responses, recruitment of PHCs, changes in capillary density, and variation of skeletal muscle fiber morphology by histology. Based on previous animal models, we anticipate that the donor population will be significantly depleted by day 7 as MSCs begin to upregulate the expression of MHC class II antigen. 21 A peak infiltration of PHCs in the more perfused regions of the anterior tibialis should occur concurrently to peak cytokine concentration around this time. Capillary formation should continue to expand secondary to PHC recruitment until the last time point at 21 days. CHAMP is designed to deliver critical evidence of the safety profile of IM injection of MSCs in CLI. Tissues harvested from the participants receiving both cBMA and MSCs will provide data that may elucidate the MSC therapeutic mechanism. Comparison to concurrent non-CHAMP risk factor-matched BKA patients at the same institution will provide controls to assess improvements in wound complications. As the next iteration after the conclusion of CHAMP, we hope to proceed with a larger, randomized controlled trial with escalating MSC dosages powered to provide outcomes data for real-world use.
CONCLUSIONS
Because CHAMP aims to harvest human tissue after IM injection of MSCs and cBMA at time points relevant to tissue reparation and cell survival, it will have the unique ability to provide a vital description of the in vivo biologic activity of MSCs and cBMA in ischemic limbs undergoing BKA. 
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